Virpax Pharmaceuticals Inc (VRPX)

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop its PES200 product candidate to manage post-traumatic stress disorder (PTSD) and its MMS019 product candidate to inhibit viral replication caused by influenza or SARS-CoV-2.

View recent insider trading info

Funds Holding VRPX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding VRPX BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

84.7 Thousand total shares from 3 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SENDROW JERROLD

  • Director
9,006 2022-05-24 3

FLOYD ERIC

  • Director
8,018 2022-05-18 2

MACK ANTHONY P. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
2,983,000 2022-05-18 4

BRUCE GERALD W

  • Director
60,000 2022-04-25 2

CHIPMAN CHRISTOPHER MICHAEL CHIEF FINANCIAL OFFICER

  • Officer
60,676 2022-01-31 2

GUDIN JEFFREY CHIEF MEDICAL OFFICER

  • Officer
  • Director
60,676 2022-01-31 2

JACOB GARY S

  • Director
12,091 2022-01-01 1

SINGH VANILA

  • Director
12,091 2022-01-01 1

JAMBULINGAM THANI

  • Director
14,113 2022-01-01 1

DUBIN MICHAEL F

  • Director
12,091 2022-01-01 3

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SENDROW JERROLD - Director

2022-05-26 18:00:27 -0400 2022-05-24 P 4,500 $1.29 a 9,006 direct

FLOYD ERIC - Director

2022-05-20 18:12:46 -0400 2022-05-18 P 4,479 $1.36 a 8,018 direct

MACK ANTHONY P. - Director - Officer CHIEF EXECUTIVE OFFICER

2022-05-20 18:15:57 -0400 2022-05-18 P 75,750 $1.34 a 252,562 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 18:45:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 18:15:04 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 17:45:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 17:15:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 16:45:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 16:15:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 15:45:04 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 15:15:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 14:45:04 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 14:15:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 13:45:04 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 13:15:04 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-27 12:45:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-24 22:15:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-24 21:45:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-24 21:15:04 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-24 20:45:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-24 20:15:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-24 19:45:03 UTC -16.6763 18.2463 150000
VIRPAX PHARMACEUTICALS INC VRPX 2022-06-24 19:15:03 UTC -16.6763 18.2463 150000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund VRPX -500.0 shares, $-1110.0 2022-03-31 N-PORT

Elevate your investments